Diagnosis and Treatment of the Stage IV Cystocele

Haemoptysis in third trimester-sole manifestation of stage IV gestational choriocarcinoma

BMJ Case Reports ◽

10.1136/bcr-2021-241870 ◽

2021 ◽

Vol 14 (4) ◽

pp. e241870

Author(s):

Brinda Basida ◽

Nirav Zalavadiya ◽

Suman Khicher ◽

Russel York

Keyword(s):

Young Woman ◽

Stage Iv ◽

Diagnosis And Treatment ◽

Advanced Stage ◽

Third Trimester ◽

Rare Neoplasm ◽

Gestational Choriocarcinoma ◽

Primary Origin ◽

Prompt Diagnosis

Gestational choriocarcinoma is a rare neoplasm of pregnancy that is often undiagnosed until the advanced stage manifests with metastatic complications. Herein, we present a case of a 22-year-old young woman with metastatic gestational choriocarcinoma with unidentified primary origin, who presented with haemoptysis as a chief problem in her third trimester. The case emphasises on the rarity of this neoplasm in a viable pregnancy. Prompt diagnosis and treatment is the key for good maternal and fetal prognosis.

Download Full-text

Cancers With Bad and Good Survival Among Male Population of Northeast India

Journal of Global Oncology ◽

10.1200/jgo.18.22100 ◽

2018 ◽

Vol 4 (Supplement 2) ◽

pp. 39s-39s

Author(s):

M. Kalita ◽

J.D. Sharma ◽

N. Baishya ◽

A.C. Kataki

Keyword(s):

Survival Rate ◽

Cancer Survival ◽

Survival Rates ◽

Cancer Control ◽

Stage Iv ◽

Northeast India ◽

Diagnosis And Treatment ◽

Good Survival ◽

Male Population ◽

Lower Survival Rate

Background: The northeast region of India has an overall high incidence, mortality and lower survival rate of cancer in the country, an annual expected of around 40,000 were diagnosed with cancer every year in this region. Mortality rate due to cancer in northeastern India is increasing mainly because of difficulties in accessing the facilities for cancer diagnosis and treatment, socioeconomic conditions, lack of awareness, taboo, misconception and wide disparity in both diagnosis and treatment of cancers among the eight different states (regions) within northeast India. Furthermore, affordability of cancer care remains a major challenge in this part of India for effective cancer control. Aim: This study was conducted with a vision to provide an idea about the cancer survival pattern of 45 million of people living in the northeastern region of India with correlation to time at diagnosis and treatment competition status. Methods: All the cases registered with a history of cancer in between 2010-2014 calendar years. Five year observed survival was calculated based on all the followed up until 2017. Three categories were made for treatment-wise survival analysis, 1) those that have completed cancer treatment 2) those that did not completed treatment 3) those who have not taken any cancer directed treatment. The 5-year survival rates were generated by using the SPSS V19 software. Kaplan-Meier method was used to generate the statistics. Results: The five years overall survival for all cancers in men is 24.3% with earlier stage at diagnosis has a better survival (Stage I, 52.1%) than later stage (Stage IV, 18.8%) at diagnosis. Completed course of cancer directed treatment found to be playing a significant role in enhancing the survival among the patients. The five-year survival for completed cancer directed treatment is 27.5% followed by 12.5% for incomplete and 8.5% for those with no cancer directed treatment group. Inequality in survival was observed among different sites of cancer, as some cancers harm younger people more than others. The five year observed survival for all sites was ranges from 0% to 75.8%. Cancer of liver (0%), pancreas (0%), lung (2.4%), gallbladder (7.9%) and stomach (10.3%) is found as more lethal than other cancers as the five years survival was in-between the range 0%-10%. Cancer of Hodgkin lymphoma (75.8%) has the highest five year cancer survival rate followed by testis (60.1%), breast-male (55.3%), penis (49.7%) and skin cancer (49.1%). The prostate cancer (19.0%) rate is very low compared with other global parts of the world where it reaches around 100% in many countries. Advances in early detection and treatment can enhance the survival rate in these regions. Conclusion: The 5-year survival showed an increasing survival with decreasing in stage at the time of diagnosis and decreasing in number of decline treatment percentage among northeastern population.

Download Full-text

Clinical investigation into the initial diagnosis and treatment of 539 patients with stage IV lung cancer

OncoTargets and Therapy ◽

10.2147/ott.s125108 ◽

2017 ◽

Vol Volume 10 ◽

pp. 535-541 ◽

Cited By ~ 2

Author(s):

Qian Shao ◽

Shanshan Liu ◽

Wei Wang ◽

yingjie zhang ◽

Fengxiang Li ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Investigation ◽

Stage Iv ◽

Initial Diagnosis ◽

Diagnosis And Treatment ◽

Stage Iv Lung Cancer

Download Full-text

Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients

Bioscience Reports ◽

10.1042/bsr20180322 ◽

2018 ◽

Vol 38 (4) ◽

Cited By ~ 17

Author(s):

Ying-Chi Yang ◽

Dong Wang ◽

Lan Jin ◽

Hong-Wei Yao ◽

Jing-Hui Zhang ◽

...

Keyword(s):

Late Stage ◽

Gene Mutations ◽

Stage Iv ◽

Circulating Tumor Dna ◽

Diagnosis And Treatment ◽

Response To Treatment ◽

Non Invasive ◽

Patient Prognosis ◽

Colorectal Cancer Patients ◽

Tumor Dna

Characterization, diagnosis, and treatment of colorectal cancers (CRC) is difficult due to limited biopsy information, impracticality of repeated biopsies, and cancer biomarker fallibility. Circulating tumor DNA (ctDNA) has recently been investigated as a non-invasive way to gain representative gene mutations in tumors, in addition to monitoring disease progression and response to treatment. We analyzed ctDNA mutations and concentrations in 47 early- and late-stage CRC patients using a targetted sequencing approach using a panel that covers 50 cancer-related genes. ctDNA mutations in 37 genes were identified in 93.6% of the patients (n=47). The results showed that TP53, PIK3CA, APC, and EGFR were the most frequently mutated genes. Stage IV patients had significantly higher ctDNA concentration than Stage I patients, and increased ctDNA concentration correlated with increased tumor size. Additionally, ctDNA detection was found to be a greater predictor of disease when compared with five known commonly used tumor biomarkers. The present study supports the use of ctDNA as a liquid biopsy to gain clinical tumor information that may facilitate early diagnosis and treatment and improve CRC patient prognosis.

Download Full-text

Malignant Uterine Neoplasms Attended at a Brazilian Regional Hospital: 16-years Profile and Time Elapsed for Diagnosis and Treatment

Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics ◽

10.1055/s-0040-1718434 ◽

2021 ◽

Author(s):

Elaine Cristina Candido ◽

Nelio Neves Veiga Junior ◽

Monique Possari Minari ◽

Maria Carolina Szymanski Toledo ◽

Daniela Angerame Yela ◽

...

Keyword(s):

Stage Iv ◽

Abnormal Uterine Bleeding ◽

Diagnostic Methods ◽

Diagnosis And Treatment ◽

Cancer Center ◽

Trend Test ◽

Cancer Stage ◽

Uterine Neoplasms ◽

Initial Symptoms ◽

The Impact

Abstract Objective The present study aims to evaluate the profile of endometrial carcinomas and uterine sarcomas attended in a Brazilian cancer center in the period from 2001 to 2016 and to analyze the impact of time elapsed from symptoms to diagnoses or treatment in cancer stage and survival. Methods This observational study with 1,190 cases evaluated the year of diagnosis, age-group, cancer stage and histological type. A subgroup of 185 women with endometrioid histology attended in the period from 2012 to 2017 was selected to assess information about initial symptoms, diagnostic methods, overall survival, and to evaluate the influence of the time elapsed from symptoms to diagnosis and treatment on staging and survival. The statistics used were descriptive, trend test, and the Kaplan-Meier method, with p-values < 0.05 for significance. Results A total of 1,068 (89.7%) carcinomas (77.2% endometrioid and 22.8% non-endometrioid) and 122 (10.3%) sarcomas were analyzed, with an increasing trend in the period (p < 0.05). Histologies of non-endometrioid carcinomas, G3 endometrioid, and carcinosarcomas constituted 30% of the cases. Non-endometrioid carcinomas and sarcomas were more frequently diagnosed in patients over 70 years of age and those on stage IV (p < 0.05). The endometrioid subgroup with 185 women reported 92% of abnormal uterine bleeding and 43% diagnosis after curettage. The average time elapsed between symptoms to diagnosis was 244 days, and between symptoms to treatment was 376 days, all without association with staging (p = 0.976) and survival (p = 0.160). Only 12% of the patients started treatment up to 60 days after diagnosis. Conclusion The number of uterine carcinoma and sarcoma cases increased over the period of 2001 to 2016. Aggressive histology comprised 30% of the patients and, for endometrioid carcinomas, the time elapsed between symptoms and diagnosis or treatment was long, although without association with staging or survival.

Download Full-text